Click image to view it in full size

The Electrophysiology (EP) service line has grown leaps and bounds in the past decade due to myriad of factors including advancement in interventional imaging, improvement in catheters for effective ablation procedures and introduction of robotic navigation systems for safe and efficient procedures. The demand for minimally invasive EP procedures is expected to accelerate in the next three years due to rising prevalence of cardiac arrhythmias, increase in number of EP centers with availability of skilled electrophysiolosists globally, and preference for micro-invasive ablation procedures for instant improvement in patient outcomes in lieu of long term medication management for conditions like Atrial Fibrillation.

Though prevalence of cardiac arrhythmias requiring EP therapy is high globally, a lot of cases are undiagnosed due to the lack of awareness among patients and primary care physicians and lack facilities resulting in poor treatment adoption. Majority of procedures performed in EP lab is done for treating atrial fibrillation (AFib) which is the top cause of blood clots that lead to stroke, and persons with the condition are five times more likely to suffer a fatal stroke. The prevalence of AFib is about 3% of the general population and is expected to double over the next 30 years. The EP landscape not only faces challenges in appropriate diagnosis on condition due to low awareness and, monitoring of post-therapy prognosis and tracking outcomes remains poor. With EP therapies moving away from conventional catheter therapies to intelligent navigation using robotics and AI and advanced cardiac mapping, entrenched incumbents will scout for innovative companies to sustain their leadership. As with other minimally invasive surgeries, EP therapies is expected to transition to ambulatory setting, and device companies need to meet a different set of needs – improving technology efficacy resulting in improved outcome while decreasing cost of care.